0000856984 2025-01-01 2025-12-31 0000856984 2025-06-30 0000856984 2026-03-30 0000856984 2025-12-31 0000856984 2024-12-31 0000856984 us-gaap:SeriesAPreferredStockMember 2025-12-31 0000856984 us-gaap:SeriesAPreferredStockMember 2024-12-31 0000856984 USAQ:SeriesATwoPreferredStockMember 2025-12-31 0000856984 USAQ:SeriesATwoPreferredStockMember 2024-12-31 0000856984 2024-01-01 2024-12-31 0000856984 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000856984 USAQ:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000856984 us-gaap:CommonStockMember 2023-12-31 0000856984 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000856984 us-gaap:RetainedEarningsMember 2023-12-31 0000856984 2023-12-31 0000856984 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0000856984 USAQ:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0000856984 us-gaap:CommonStockMember 2024-12-31 0000856984 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000856984 us-gaap:RetainedEarningsMember 2024-12-31 0000856984 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0000856984 USAQ:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0000856984 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000856984 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0000856984 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000856984 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-12-31 0000856984 USAQ:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-12-31 0000856984 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0000856984 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-12-31 0000856984 us-gaap:RetainedEarningsMember 2025-01-01 2025-12-31 0000856984 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0000856984 USAQ:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0000856984 us-gaap:CommonStockMember 2025-12-31 0000856984 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000856984 us-gaap:RetainedEarningsMember 2025-12-31 0000856984 USAQ:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0000856984 USAQ:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000856984 us-gaap:PatentsMember 2025-12-31 0000856984 USAQ:WebDomainMember 2025-01-01 2025-12-31 0000856984 us-gaap:TrademarksMember 2025-01-01 2025-12-31 0000856984 USAQ:AllergyDiagnosticKitSalesMember 2025-01-01 2025-12-31 0000856984 USAQ:AllergyDiagnosticKitSalesMember 2024-01-01 2024-12-31 0000856984 USAQ:IntegratedServiceProgramMember 2025-01-01 2025-12-31 0000856984 USAQ:IntegratedServiceProgramMember 2024-01-01 2024-12-31 0000856984 USAQ:ImmunotherapyTreatmentSalesMember 2025-01-01 2025-12-31 0000856984 USAQ:ImmunotherapyTreatmentSalesMember 2024-01-01 2024-12-31 0000856984 USAQ:ClinicalStudyRevenueMember 2025-01-01 2025-12-31 0000856984 USAQ:ClinicalStudyRevenueMember 2024-01-01 2024-12-31 0000856984 USAQ:SubscriptionRevenueMember 2025-01-01 2025-12-31 0000856984 USAQ:SubscriptionRevenueMember 2024-01-01 2024-12-31 0000856984 us-gaap:ShippingAndHandlingMember 2025-01-01 2025-12-31 0000856984 us-gaap:ShippingAndHandlingMember 2024-01-01 2024-12-31 0000856984 USAQ:TrainingAndOtherRevenueMember 2025-01-01 2025-12-31 0000856984 USAQ:TrainingAndOtherRevenueMember 2024-01-01 2024-12-31 0000856984 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2025-12-31 0000856984 us-gaap:PatentsMember 2024-12-31 0000856984 USAQ:WebDomainMember 2025-12-31 0000856984 USAQ:WebDomainMember 2024-12-31 0000856984 us-gaap:TrademarksMember 2025-12-31 0000856984 us-gaap:TrademarksMember 2024-12-31 0000856984 USAQ:MedScienceResearchGroupMember 2021-06-23 2021-06-23 0000856984 USAQ:PurchaseAgreementMember 2021-06-23 0000856984 USAQ:PurchaseAgreementMember 2025-12-31 0000856984 USAQ:PurchaseAgreementMember 2024-12-31 0000856984 2025-11-12 2025-11-12 0000856984 USAQ:NoteOneShareholderMember USAQ:ConvertibleNotesPayableOneMember 2025-12-31 0000856984 USAQ:NoteOneShareholderMember USAQ:ConvertibleNotesPayableOneMember 2024-12-31 0000856984 USAQ:NoteTwoMercerNoteMember USAQ:ConvertibleNotesPayableTwoMember 2025-12-31 0000856984 USAQ:NoteTwoMercerNoteMember USAQ:ConvertibleNotesPayableTwoMember 2024-12-31 0000856984 USAQ:NoteThreeMercerNoteTwoMember USAQ:ConvertibleNotesPayableThreeMember 2025-12-31 0000856984 USAQ:NoteThreeMercerNoteTwoMember USAQ:ConvertibleNotesPayableThreeMember 2024-12-31 0000856984 us-gaap:ConvertibleNotesPayableMember 2025-12-31 0000856984 us-gaap:ConvertibleNotesPayableMember 2024-12-31 0000856984 USAQ:NoteOneShareholderMember USAQ:ConvertibleNotesPayableOneMember 2021-05-07 0000856984 USAQ:NoteOneShareholderMember USAQ:ConvertibleNotesPayableOneMember 2021-05-07 2021-05-07 0000856984 USAQ:EightLakhSixThousandNoteMember USAQ:ConvertibleNotesPayableThreeMember USAQ:SecuritiesPurchaseAgreementMember 2021-08-10 0000856984 USAQ:EightLakhSixThousandNoteMember USAQ:ConvertibleNotesPayableThreeMember USAQ:SecuritiesPurchaseAgreementMember 2021-08-10 2021-08-10 0000856984 USAQ:EightLakhSixThousandNoteMember USAQ:ConvertibleNotesPayableFourMember USAQ:SecuritiesPurchaseAgreementMember USAQ:MercerStreetGlobalOpportunityFundLLCMember 2022-08-10 0000856984 USAQ:EightLakhSixThousandNoteMember USAQ:SecuritiesPurchaseAgreementMember USAQ:MercerStreetGlobalOpportunityFundLLCMember 2021-11-11 2021-11-11 0000856984 USAQ:EightLakhSixThousandNoteMember USAQ:SecuritiesPurchaseAgreementMember USAQ:MercerStreetGlobalOpportunityFundLLCMember 2021-11-11 0000856984 USAQ:EightLakhSixThousandNoteMember USAQ:ConvertibleNotesPayableThreeMember USAQ:SecuritiesPurchaseAgreementMember 2021-11-11 0000856984 USAQ:EightLakhSixThousandNoteMember USAQ:ConvertibleNotesPayableFourMember USAQ:SecuritiesPurchaseAgreementMember USAQ:MercerStreetGlobalOpportunityFundLLCMember 2022-07-19 0000856984 USAQ:EightLakhSixThousandNoteMember USAQ:ConvertibleNotesPayableThreeMember USAQ:SecuritiesPurchaseAgreementMember USAQ:MercerStreetGlobalOpportunityFundLLCMember 2022-07-27 0000856984 USAQ:EightLakhSixThousandNoteMember USAQ:ConvertibleNotesPayableThreeMember USAQ:SecuritiesPurchaseAgreementMember USAQ:MercerStreetGlobalOpportunityFundLLCMember 2022-07-26 2022-07-27 0000856984 USAQ:EightLakhSixThousandNoteMember 2023-10-05 2023-10-05 0000856984 USAQ:EightLakhSixThousandNoteMember 2023-10-05 0000856984 USAQ:EightLakhSixThousandNoteMember 2024-03-04 2024-03-04 0000856984 USAQ:EightLakhSixThousandNoteMember 2024-03-04 0000856984 USAQ:EightLakhSixThousandNoteMember 2025-01-06 0000856984 USAQ:EightLakhSixThousandNoteMember 2025-01-06 2025-01-06 0000856984 USAQ:EightLakhSixThousandNoteMember 2025-01-13 0000856984 USAQ:EightLakhSixThousandNoteMember 2025-01-13 2025-01-13 0000856984 USAQ:EightLakhSixThousandNoteMember 2025-02-19 2025-02-20 0000856984 USAQ:EightLakhSixThousandNoteMember 2024-01-01 2024-12-31 0000856984 2025-11-18 0000856984 2025-11-18 2025-11-18 0000856984 USAQ:FourLakhFourtyThousandNoteMember USAQ:ConvertibleNotesPayableFourMember USAQ:SecuritiesPurchaseAgreementMember USAQ:MercerStreetGlobalOpportunityFundLLCMember 2022-07-19 0000856984 USAQ:FourLakhFourtyThousandNoteMember USAQ:ConvertibleNotesPayableFourMember USAQ:SecuritiesPurchaseAgreementMember USAQ:MercerStreetGlobalOpportunityFundLLCMember 2022-07-19 2022-07-19 0000856984 USAQ:FourLakhFourtyThousandNoteMember USAQ:ConvertibleNotesPayableFourMember USAQ:SecuritiesPurchaseAgreementMember USAQ:MercerStreetGlobalOpportunityFundLLCMember 2023-07-19 0000856984 USAQ:FourLakhFourtyThousandNoteMember 2025-02-19 2025-02-20 0000856984 USAQ:FourLakhFourtyThousandNoteMember 2024-01-01 2024-12-31 0000856984 USAQ:FourLakhFourtyThousandNoteMember USAQ:ConvertibleNotesPayableFourMember USAQ:SecuritiesPurchaseAgreementMember USAQ:MercerStreetGlobalOpportunityFundLLCMember 2025-12-31 0000856984 USAQ:FourLakhFourtyThousandNoteMember USAQ:ConvertibleNotesPayableThreeMember USAQ:SecuritiesPurchaseAgreementMember 2025-12-31 0000856984 USAQ:FourLakhFourtyThousandNoteMember USAQ:ConvertibleNotesPayableThreeMember 2024-12-31 0000856984 USAQ:FourLakhFourtyThousandNoteMember USAQ:ConvertibleNotesPayableThreeMember 2024-01-01 2024-12-31 0000856984 us-gaap:PrivatePlacementMember USAQ:SubscriptionAgreementsMember 2025-12-26 2025-12-26 0000856984 us-gaap:PrivatePlacementMember USAQ:SubscriptionAgreementsMember 2025-12-26 0000856984 us-gaap:SeriesAPreferredStockMember 2021-06-21 0000856984 USAQ:SeriesA2PreferredStockMember 2021-12-29 2021-12-30 0000856984 USAQ:SeriesA2PreferredStockMember 2025-01-01 2025-12-31 0000856984 USAQ:SeriesA2PreferredStockMember us-gaap:CommonStockMember 2025-01-01 2025-12-31 0000856984 USAQ:SeriesA2PreferredStockMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000856984 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-12-31 0000856984 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0000856984 us-gaap:WarrantMember 2025-01-01 2025-12-31 0000856984 us-gaap:WarrantMember 2024-01-01 2024-12-31 0000856984 USAQ:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-12-31 0000856984 USAQ:ResearchAndDevelopmentExpensesMember 2024-01-01 2024-12-31 0000856984 USAQ:GeneralAndAdministrativeExpensesMember 2025-01-01 2025-12-31 0000856984 USAQ:GeneralAndAdministrativeExpensesMember 2024-01-01 2024-12-31 0000856984 USAQ:WarrantOneMember 2024-01-01 2024-12-31 0000856984 USAQ:WarrantOneMember 2024-12-31 0000856984 us-gaap:WarrantMember 2024-12-31 0000856984 USAQ:OptionOneMember 2025-01-01 2025-12-31 0000856984 USAQ:OptionOneMember 2025-12-31 0000856984 USAQ:OptionTwoMember 2025-01-01 2025-12-31 0000856984 USAQ:OptionTwoMember 2025-12-31 0000856984 us-gaap:OptionMember 2025-12-31 0000856984 USAQ:WarrantOneMember 2025-01-01 2025-12-31 0000856984 USAQ:WarrantOneMember 2025-12-31 0000856984 us-gaap:WarrantMember 2025-12-31 0000856984 us-gaap:NonrelatedPartyMember 2025-12-31 0000856984 us-gaap:NonrelatedPartyMember 2024-12-31 0000856984 us-gaap:RelatedPartyMember 2025-12-31 0000856984 us-gaap:RelatedPartyMember 2024-12-31 iso4217:USD shares iso4217:USD shares pure false FY 0000856984

10-K true 2025-12-31 --12-31 2025 false 0-19041 QHSLab, Inc. NV 30-1104301 901 Northpoint Parkway Suite 302 West Palm Beach FL 33407 (929) 379-6503 Common Stock, $0.0001 Par Value USAQ No No Yes Yes Non-accelerated Filer true false false false false 1562056 15032788 At QHSLab, Inc., we prioritize the security and privacy of all data, with a special emphasis on the personal health, financial, and insurance information entrusted to us by our medical practice clients and their patient electronic personal health information (ePHI). Recognizing the unique vulnerabilities of the digital medicine sector, we have developed an internal cybersecurity risk management framework that incorporates industry-leading practices and technologies to safeguard against cyber threats. Our Approach to Cybersecurity Risk Management Our cybersecurity framework is built around a comprehensive strategy that includes ongoing risk assessment, threat detection, swift incident response, and continuous improvement of our cybersecurity defenses. Key elements of our program include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Framework Adoption: Utilization of the CIS Critical Security Controls (CIS Controls) as a reference framework to benchmark and inform the design of the Company’s cybersecurity controls.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cybersecurity Assessments: Regular assessments of our cybersecurity through both internal evaluations and planned periodical third-party audits, ensuring adherence to the highest standards of security.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Training and Awareness: Mandatory cybersecurity training for all employees upon onboarding and through annual refreshers, fostering a culture of security awareness across the organization.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incident Response and Preparedness: A well-defined incident response plan that enables us to quickly identify, contain, and mitigate the impact of cybersecurity incidents.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Third-Party Risk Management: Evaluation of third-party vendors’ security practices to ensure they meet our strict standards, especially when they have access to sensitive data.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Investment in Security Infrastructure: Investment in cybersecurity technologies and infrastructure to stay ahead of emerging threats.</td></tr> </table> During the year ended December 31, 2025, the Company has not identified risks from cybersecurity threats, including as a result of prior cybersecurity incidents, that have materially affected or are reasonably anticipated to materially affect the Company, including its business strategy, results of operations, or financial condition. Nevertheless, the Company recognizes cybersecurity threats are ongoing and evolving. For more information on the Company’s cybersecurity risks, refer to Item 1A, “Risk Factors”. Governance and Oversight Cybersecurity governance at QHSLab, Inc. is a board-level priority, with oversight integrated into enterprise risk management. Insurance and Risk Mitigation Cyber insurance coverage is reviewed periodically to align with the Company’s evolving risk profile. Incident Response and Risk Management at QHSLab, Inc. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20250101__20251231_zqDTsvlzCCf">Central to our enterprise risk management efforts, we have developed a comprehensive <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zjOBXX8R8yNc">incident response plan to swiftly and effectively address cybersecurity incidents. This plan is a cornerstone of our commitment to maintaining the highest levels of data security and patient privacy. Incident Assessment and Response Procedures <p class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_986_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20250101__20251231_zLP1Prif7isk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Upon identification of a potential cybersecurity incident, management initiates a structured initial assessment, guided by predefined criteria to gauge the incident’s severity and potential impact. This evaluation is critical for determining the scope of the incident and crafting an appropriate response. The process includes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Immediate Assessment: Conducted by the incident response team to determine the incident’s nature, scope, and potential impact on QHSLab, Inc.’s operations and sensitive patient data.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Elevation Protocol: Incidents with significant potential impact are promptly escalated to senior IT security team members for further review. This ensures that high-level expertise is applied to complex or severe cybersecurity events.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Material Impact Analysis: Management assesses the potential for substantial harm to the organization, considering factors such as data integrity, patient privacy, and operational continuity.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Public Disclosure Considerations: In alignment with regulatory requirements and our commitment to transparency, management evaluates the necessity and timing for public disclosure, balancing patient privacy, legal obligations, and public interest.</td></tr> </table> Commitment to Continuous Improvement Recognizing the dynamic nature of cyber threats, particularly in the digital medicine sector, our incident response plan is subject to ongoing review and refinement. We will regularly update our procedures to incorporate any lessons learned from past incidents and emerging best practices in cybersecurity. Central to our enterprise risk management efforts, we have developed a comprehensive <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zjOBXX8R8yNc">incident response plan to swiftly and effectively address cybersecurity incidents. This plan is a cornerstone of our commitment to maintaining the highest levels of data security and patient privacy true Upon identification of a potential cybersecurity incident, management initiates a structured initial assessment, guided by predefined criteria to gauge the incident’s severity and potential impact. This evaluation is critical for determining the scope of the incident and crafting an appropriate response. true 6920 We have audited the accompanying consolidated balance sheets of QHSLab, Inc. (the Company) as of December 31, 2025 and 2024, and the related consolidated statements of operations, stockholders’ equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2025, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America. Astra Audit & Advisory LLC Tampa, Florida

636157

157168

190610

196089

35790

41779

20452

25791

883009

420827

18616

1287997

1360109

2171006

1799552

326431

340962

17858

343945

85571

438254

20000

1284147

449860

2407308

96218

546078

2407308

10000000

0.0001

1080092

108

0.0001

2644424

264

900000000

0.0001

15032788

10806527

1503

1081

5526604

3722141

-3903551

-4331350

1624928

-607756

2171006

1799552

2691741

2131926

880892

774036

1810849

1357890

683477

509065

439143

276496

484873

294479

72112

1679605

1152152

131244

205738

237413

465055

665755 102251

457417

-259239

457417

-259239

0.04

-0.03

0.02

-0.03

11297235

10288458

19342119

10288458

1080092

108

2644424

264

9735508

974

3606295

-3983258

-375617

480000

11952

12000

491019

-49

-88804

88853

100000

15090

15100

-259239

1080092

108

2644424

264

10806527

1081

3722141

-4331350

-607756

1080092

108

2644424

264

10806527

1081

3722141

-4331350

-607756

796827

303720

303799

1568432

157

950313

950470

1666663

167

416585

416752

83246 83246

94339

-9

-29609

29618

100000

20990

21000

457417

1080092

108

2644424

264

15032788

1503

5526604

-3903551

1624928

1080092

108

2644424

264

15032788

1503

5526604

-3903551

1624928

457417

-259239

7276

4278

90728

146575

21000

15100

1145695

-479940

102251

1797

128985

-5989

16598

-5339

17804

-14531

262055

170201

137055

178118

142437

90968

10300

14504

114400

146500

89991

193651

499998

300000

300871

-36851

478989

105586

157168

51582

636157

157168

80713

245995

1254269 12000 29618 88853

Note 1. The Company QHSLab, Inc. (the “Company” or the “Registrant”) was incorporated in Delaware on September 1, 1983. In 2019, the Company became engaged in value-based healthcare, informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. On September 23, 2021, the Company changed its state of incorporation from Delaware to Nevada. On April 19, 2022, the Company changed its name to QHSLab, Inc. The Company is a medical device technology and software-as-a-service (“SaaS”) company focused on enabling primary care physicians (“PCP’s”) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures and providing physicians’ offices with agreed-upon clinical decision support, digital health assessments, administrative workflow, and reimbursement support services.

Note 2. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has only recently operated profitably, has been highly leveraged and has only recently begun to generate cash from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The continuation of the Company’s business is dependent upon its ability to achieve increased positive cash flows and continual profitability and, pending such achievement, future issuances of equity or other financings to fund ongoing operations. However, access to such funding may not be available on commercially reasonable terms, if at all. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note 3. Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). In the opinion of management, the accompanying audited consolidated financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. Segment Information The Company operates as a single operating segment and single reportable segment. Operating segments are defined as components of a business that can earn revenue and incur expenses and for which discrete financial information is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance. The Company’s CODM, the Chief Executive Officer, allocates resources and assesses performance based upon consolidated financial information due to the interconnected relationship of the Company’s products to the same customers, therefore manages its business as a single operating segment. See Note 13 - Segment Information for additional information. Accounting Policies Use of Estimates: The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates. Principles of Consolidation: The consolidated financial statements include the accounts of QHSLab, Inc. and its wholly owned subsidiaries USAQ Corporation, Inc. and Medical Practice Income, Inc. All significant inter-company balances and transactions have been eliminated. Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. Cash and cash equivalents are maintained at banks believed to be stable, occasionally at amounts in excess of federally insured limits, which represents a concentration of credit risk. The Company has not experienced any losses on deposits of cash and cash equivalents to date. Accounts Receivable: The Company extends unsecured credit to its customers on a regular basis. Management monitors the payments on outstanding balances and adjusts the reserve for uncollectible balances to represent future expected credit losses over the life of the receivables based on past experience, current information and forward-looking economic considerations. The Company controls its credit risk related to accounts receivable through credit approvals and monitoring. The Company had no customers that generated 10% or more of its revenue during 2025. As of December 31, 2025, two customers comprised greater than 10% of the outstanding accounts receivable balance at <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zzoZRKs1LV41" title="Concentration risk percentage">16.7% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z7TA9MMA5T11" title="Concentration risk percentage">10.2%. Inventories: Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. The Company uses actual costs to determine its cost basis for inventories. Inventories consist of only finished goods. Management monitors inventory based on forecasted sales and existing inventory levels. Based on inventory turnover and low on-hand inventory levels, management has determined there was no need for a reserve for slow-moving and obsolete inventories as of December 31, 2025 and 2024. Capitalized Software Development Costs: Software development costs for internal-use software are accounted for in accordance with Accounting Standards Codification (“ASC”) 350-40, Internal-Use Software. Development costs that are incurred during the application development stage begin to be capitalized when two criteria are met: (i) the preliminary project stage is completed and (ii) it is probable that the software will be completed and used for its intended function. Capitalization ceases once the software is substantially complete and ready for its intended use. Costs incurred during the preliminary project stage of software development and post-implementation operating stages are expensed as incurred. Amortization is calculated on a straight-line basis over three years which is the estimated economic life of the software and is included in the cost of revenue on the consolidated statements of operations. The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Intangible Assets: Intangible assets represent the value the Company paid to acquire assets including a trademark, patent and web domain on June 23, 2021. The provisional allocation of the purchase price to each of these assets was determined based on ASC 805-50-30, Business Combination, Related Issues, Initial Measurement. These assets are accounted for in accordance with ASC 350-30, Intangibles, General Intangibles Other Than Goodwill. The cost of the assets is amortized over the remaining useful life of the assets as follows: Schedule of Indefinite-Lived Intangible Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1.5in">U.S. Method Patent</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVp1sK0oZk9j" title="Finite-lived intangible assets, amortization method">13.4 years at acquisition</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Web Domain</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ImpairedIntangibleAssetDescription_c20250101__20251231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebDomainMember_zdHkSRzlAJb3" title="Impaired intangible asset">Indefinite life</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Trademark</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ImpairedIntangibleAssetDescription_c20250101__20251231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_znlwtVV7cmbf" title="Impaired intangible asset">Indefinite life</td></tr> </table> The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances occur which may result in an impact to the value of the assets. Convertible Notes Payable: The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under Accounting Standards Update (“ASU”) No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. ASU 2020-06 removes the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removes certain settlement conditions that were required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share calculation for convertible instruments. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Revenue Recognition: Pursuant to ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, the Company recognizes revenue upon transfer of control of goods or services, in an amount that reflects the consideration that is expected to be received in exchange for those goods. The Company does not allow for the return of products and therefore does not establish an allowance for returns. To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">identify the contract(s) with a customer;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(ii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">identify the performance obligations in the contract(s);</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(iii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">determine the transaction price;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(iv)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">allocate the transaction price to the performance obligations in the contract(s); and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(v)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">recognize revenue when (or as) the Company satisfies a performance obligation.</td></tr> </table> The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer. Beginning April 1, 2025, the Company changed its policy of when title transitions to its customers from upon delivery to upon shipment. Delivery typically occurred within one or two days of shipment, and the Company limited shipping ahead of the end of each reporting period to allow time for delivery. Revenue continues to be recorded when title passes to the customer and, as a result, the change did not have a material impact on the Company’s previously issued consolidated financial statements. The Company includes shipping and handling fees billed to customers in revenue. The Company also generates revenue through Software-as-a-Service (SaaS) agreements whereby the Company provides physicians’ practices access to its proprietary internally-developed software QHSLab that provides clinical decision support and patient monitoring. The agreements provide for either monthly or annual access to the software. The access to the system begins immediately and revenue is recognized over the agreement term. The Company provides administrative, billing and clinical decision support services utilizing QHSLab. Revenue is recognized each month based on actual services provided during that month. The Company has entered into an agreement with a third party to provide clinical research services utilizing QHSLab. The agreement details the performance obligations of the Company and revenue is recognized as those obligations are met. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract. The Company’s revenues consisted of the following: Schedule of Revenue Recognition <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20251231_zwXc8JFrGMh4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zNM5AKcX0SJ1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--AllergyDiagnosticKitSalesMember_maGPzsrL_zoJXeVBTkSKf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Allergy Diagnostic Kit Sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">823,108</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">832,987</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--IntegratedServiceProgramMember_maGPzsrL_ziKy6CZlvhOb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Integrated Service Program Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,121,134</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">643,211</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ImmunotherapyTreatmentSalesMember_maGPzsrL_zqkdGpbEGfQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Immunotherapy Treatment Sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">487,762</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">409,319</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalStudyRevenueMember_maGPzsrL_zOeyNsyioiM1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical Study Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,650</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SubscriptionRevenueMember_maGPzsrL_ztmONxrypgvk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Subscription Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,731</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,523</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_maGPzsrL_zPs1V8XjJ5f4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shipping & Handling</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,892</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TrainingAndOtherRevenueMember_maGPzsrL_zrBwzdvUpZea" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Training & Other Revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,686</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,344</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzsrL_z4StMuzmOon2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,691,741</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,131,926</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Research and Development: Research and development expense is primarily related to developing and improving methods related to the Company’s QHSLab. Research and development expenses are expensed when incurred. For the years ended December 31, 2025 and 2024, there were $484,873 and $294,479 of research and development expenses incurred, respectively. Stock-based Compensation: The Company applies the fair value method of ASC 718, Share Based Payment, in accounting for its stock-based compensation. The standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values stock-based compensation at the market price for the Company’s common stock and other pertinent factors at the grant date. Earnings Per Common Share: Basic net earnings or (loss) per share is computed using the weighted average number of common shares outstanding during the period. Diluted net earnings or (loss) per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options and warrants to purchase common stock (only if those options and warrants are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. For the year ended December 31, 2025, 8,044,884 of common equivalent shares related to Preferred Shares A and A-2 were added to the basic weighted average shares outstanding to arrive at the diluted weighted average shares outstanding. Due to the net losses reported for the year ended December 31, 2024, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for those periods. Income Taxes: The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. The Company has net operating losses of $3,903,551 which begin to expire in 2027. Future utilization of currently generated federal and state NOL and tax credit carry forwards may be subject to a substantial annual limitation due to the ownership change limitations. The annual limitation may result in the expiration of NOL and tax credit carry-forwards before full utilization. Recently Issued Accounting Standards In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires all public entities, including public entities with a single reportable segment, to expand disclosures, on an annual and interim basis, about reportable segments and requires more enhanced information about a reportable segment’s expenses, interim segment profit or loss, and how a public entity’s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. ASU 2023-07 is to be applied retrospectively to all prior periods presented in the financial statements with an effective date for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company, which has one reportable segment, has adopted ASU 2023-07 and included annual disclosures for all periods presented in the Company’s audited consolidated financial statements as of December 31, 2024 and all interim disclosures beginning with the Form 10-Q for the period ending March 31, 2025. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-09 beginning with the Form 10-Q for the period ending March 31, 2025 with minimal impact. See Note 12 – Income Taxes. This Annual Report on Form 10-K does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Use of Estimates: The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

Principles of Consolidation: The consolidated financial statements include the accounts of QHSLab, Inc. and its wholly owned subsidiaries USAQ Corporation, Inc. and Medical Practice Income, Inc. All significant inter-company balances and transactions have been eliminated.

Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. Cash and cash equivalents are maintained at banks believed to be stable, occasionally at amounts in excess of federally insured limits, which represents a concentration of credit risk. The Company has not experienced any losses on deposits of cash and cash equivalents to date.

Accounts Receivable: The Company extends unsecured credit to its customers on a regular basis. Management monitors the payments on outstanding balances and adjusts the reserve for uncollectible balances to represent future expected credit losses over the life of the receivables based on past experience, current information and forward-looking economic considerations. The Company controls its credit risk related to accounts receivable through credit approvals and monitoring. The Company had no customers that generated 10% or more of its revenue during 2025. As of December 31, 2025, two customers comprised greater than 10% of the outstanding accounts receivable balance at <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zzoZRKs1LV41" title="Concentration risk percentage">16.7% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z7TA9MMA5T11" title="Concentration risk percentage">10.2%.

0.167

0.102

Inventories: Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. The Company uses actual costs to determine its cost basis for inventories. Inventories consist of only finished goods. Management monitors inventory based on forecasted sales and existing inventory levels. Based on inventory turnover and low on-hand inventory levels, management has determined there was no need for a reserve for slow-moving and obsolete inventories as of December 31, 2025 and 2024.

Capitalized Software Development Costs: Software development costs for internal-use software are accounted for in accordance with Accounting Standards Codification (“ASC”) 350-40, Internal-Use Software. Development costs that are incurred during the application development stage begin to be capitalized when two criteria are met: (i) the preliminary project stage is completed and (ii) it is probable that the software will be completed and used for its intended function. Capitalization ceases once the software is substantially complete and ready for its intended use. Costs incurred during the preliminary project stage of software development and post-implementation operating stages are expensed as incurred. Amortization is calculated on a straight-line basis over three years which is the estimated economic life of the software and is included in the cost of revenue on the consolidated statements of operations. The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets.

Intangible Assets: Intangible assets represent the value the Company paid to acquire assets including a trademark, patent and web domain on June 23, 2021. The provisional allocation of the purchase price to each of these assets was determined based on ASC 805-50-30, Business Combination, Related Issues, Initial Measurement. These assets are accounted for in accordance with ASC 350-30, Intangibles, General Intangibles Other Than Goodwill. The cost of the assets is amortized over the remaining useful life of the assets as follows: Schedule of Indefinite-Lived Intangible Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1.5in">U.S. Method Patent</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVp1sK0oZk9j" title="Finite-lived intangible assets, amortization method">13.4 years at acquisition</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Web Domain</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ImpairedIntangibleAssetDescription_c20250101__20251231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebDomainMember_zdHkSRzlAJb3" title="Impaired intangible asset">Indefinite life</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Trademark</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ImpairedIntangibleAssetDescription_c20250101__20251231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_znlwtVV7cmbf" title="Impaired intangible asset">Indefinite life</td></tr> </table> The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances occur which may result in an impact to the value of the assets.

Schedule of Indefinite-Lived Intangible Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1.5in">U.S. Method Patent</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVp1sK0oZk9j" title="Finite-lived intangible assets, amortization method">13.4 years at acquisition</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Web Domain</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ImpairedIntangibleAssetDescription_c20250101__20251231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebDomainMember_zdHkSRzlAJb3" title="Impaired intangible asset">Indefinite life</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Trademark</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ImpairedIntangibleAssetDescription_c20250101__20251231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_znlwtVV7cmbf" title="Impaired intangible asset">Indefinite life</td></tr> </table>

P13Y4M24D

Indefinite life

Convertible Notes Payable: The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under Accounting Standards Update (“ASU”) No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. ASU 2020-06 removes the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removes certain settlement conditions that were required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share calculation for convertible instruments. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.

Revenue Recognition: Pursuant to ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, the Company recognizes revenue upon transfer of control of goods or services, in an amount that reflects the consideration that is expected to be received in exchange for those goods. The Company does not allow for the return of products and therefore does not establish an allowance for returns. To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">identify the contract(s) with a customer;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(ii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">identify the performance obligations in the contract(s);</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(iii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">determine the transaction price;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(iv)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">allocate the transaction price to the performance obligations in the contract(s); and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(v)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">recognize revenue when (or as) the Company satisfies a performance obligation.</td></tr> </table> The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer. Beginning April 1, 2025, the Company changed its policy of when title transitions to its customers from upon delivery to upon shipment. Delivery typically occurred within one or two days of shipment, and the Company limited shipping ahead of the end of each reporting period to allow time for delivery. Revenue continues to be recorded when title passes to the customer and, as a result, the change did not have a material impact on the Company’s previously issued consolidated financial statements. The Company includes shipping and handling fees billed to customers in revenue. The Company also generates revenue through Software-as-a-Service (SaaS) agreements whereby the Company provides physicians’ practices access to its proprietary internally-developed software QHSLab that provides clinical decision support and patient monitoring. The agreements provide for either monthly or annual access to the software. The access to the system begins immediately and revenue is recognized over the agreement term. The Company provides administrative, billing and clinical decision support services utilizing QHSLab. Revenue is recognized each month based on actual services provided during that month. The Company has entered into an agreement with a third party to provide clinical research services utilizing QHSLab. The agreement details the performance obligations of the Company and revenue is recognized as those obligations are met. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract. The Company’s revenues consisted of the following: Schedule of Revenue Recognition <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20251231_zwXc8JFrGMh4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zNM5AKcX0SJ1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--AllergyDiagnosticKitSalesMember_maGPzsrL_zoJXeVBTkSKf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Allergy Diagnostic Kit Sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">823,108</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">832,987</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--IntegratedServiceProgramMember_maGPzsrL_ziKy6CZlvhOb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Integrated Service Program Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,121,134</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">643,211</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ImmunotherapyTreatmentSalesMember_maGPzsrL_zqkdGpbEGfQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Immunotherapy Treatment Sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">487,762</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">409,319</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalStudyRevenueMember_maGPzsrL_zOeyNsyioiM1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical Study Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,650</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SubscriptionRevenueMember_maGPzsrL_ztmONxrypgvk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Subscription Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,731</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,523</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_maGPzsrL_zPs1V8XjJ5f4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shipping & Handling</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,892</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TrainingAndOtherRevenueMember_maGPzsrL_zrBwzdvUpZea" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Training & Other Revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,686</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,344</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzsrL_z4StMuzmOon2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,691,741</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,131,926</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The Company’s revenues consisted of the following: Schedule of Revenue Recognition <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20251231_zwXc8JFrGMh4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zNM5AKcX0SJ1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--AllergyDiagnosticKitSalesMember_maGPzsrL_zoJXeVBTkSKf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Allergy Diagnostic Kit Sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">823,108</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">832,987</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--IntegratedServiceProgramMember_maGPzsrL_ziKy6CZlvhOb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Integrated Service Program Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,121,134</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">643,211</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ImmunotherapyTreatmentSalesMember_maGPzsrL_zqkdGpbEGfQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Immunotherapy Treatment Sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">487,762</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">409,319</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalStudyRevenueMember_maGPzsrL_zOeyNsyioiM1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical Study Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,650</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SubscriptionRevenueMember_maGPzsrL_ztmONxrypgvk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Subscription Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,731</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,523</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_maGPzsrL_zPs1V8XjJ5f4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shipping & Handling</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,892</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TrainingAndOtherRevenueMember_maGPzsrL_zrBwzdvUpZea" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Training & Other Revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,686</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,344</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzsrL_z4StMuzmOon2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,691,741</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,131,926</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

823108

832987

1121134

643211

487762

409319

133650

43731

54523

41670

35892

40686

22344

2691741

2131926

Research and Development: Research and development expense is primarily related to developing and improving methods related to the Company’s QHSLab. Research and development expenses are expensed when incurred. For the years ended December 31, 2025 and 2024, there were $484,873 and $294,479 of research and development expenses incurred, respectively.

484873

294479

Stock-based Compensation: The Company applies the fair value method of ASC 718, Share Based Payment, in accounting for its stock-based compensation. The standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values stock-based compensation at the market price for the Company’s common stock and other pertinent factors at the grant date.

Earnings Per Common Share: Basic net earnings or (loss) per share is computed using the weighted average number of common shares outstanding during the period. Diluted net earnings or (loss) per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options and warrants to purchase common stock (only if those options and warrants are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. For the year ended December 31, 2025, 8,044,884 of common equivalent shares related to Preferred Shares A and A-2 were added to the basic weighted average shares outstanding to arrive at the diluted weighted average shares outstanding. Due to the net losses reported for the year ended December 31, 2024, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for those periods.

8044884

Income Taxes: The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. The Company has net operating losses of $3,903,551 which begin to expire in 2027. Future utilization of currently generated federal and state NOL and tax credit carry forwards may be subject to a substantial annual limitation due to the ownership change limitations. The annual limitation may result in the expiration of NOL and tax credit carry-forwards before full utilization.

3903551

begin to expire in 2027

Recently Issued Accounting Standards In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires all public entities, including public entities with a single reportable segment, to expand disclosures, on an annual and interim basis, about reportable segments and requires more enhanced information about a reportable segment’s expenses, interim segment profit or loss, and how a public entity’s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. ASU 2023-07 is to be applied retrospectively to all prior periods presented in the financial statements with an effective date for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company, which has one reportable segment, has adopted ASU 2023-07 and included annual disclosures for all periods presented in the Company’s audited consolidated financial statements as of December 31, 2024 and all interim disclosures beginning with the Form 10-Q for the period ending March 31, 2025. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-09 beginning with the Form 10-Q for the period ending March 31, 2025 with minimal impact. See Note 12 – Income Taxes. This Annual Report on Form 10-K does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Note 4. Accounts Receivable Accounts receivable are recorded in the consolidated balance sheets when customers are invoiced for revenue to be collected and there is an unconditional right to receive payment. Timing of revenue recognition may differ from the timing of invoicing customers resulting in deferred revenue until the Company satisfies its performance obligation. Accounts receivable are presented net of an allowance for doubtful accounts that represents future expected credit losses over the life of the receivables based on past experience, current information and forward-looking economic considerations. The beginning and ending balances of accounts receivable, net of allowance, are as follows: Schedule of Accounts Receivable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20251231_zQLSwFMpWqO4" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241231_zhPASo9RXH2b" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsReceivableGrossCurrent_iI_maARNCzPzS_zXfmlTbsP66b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accounts receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">220,610</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">218,813</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_di_msARNCzPzS_zcqLoaxopyQk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(30,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(22,724</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--AccountsReceivableNetCurrent_iTI_mtARNCzPzS_zko1dSxg6vCf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accounts receivable, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">190,610</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">196,089</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

Schedule of Accounts Receivable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20251231_zQLSwFMpWqO4" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241231_zhPASo9RXH2b" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsReceivableGrossCurrent_iI_maARNCzPzS_zXfmlTbsP66b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accounts receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">220,610</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">218,813</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_di_msARNCzPzS_zcqLoaxopyQk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(30,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(22,724</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--AccountsReceivableNetCurrent_iTI_mtARNCzPzS_zko1dSxg6vCf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accounts receivable, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">190,610</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">196,089</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

220610

218813

30000

22724

190610

196089

Note 5. Capitalized Software and Intangible Assets Non-current assets consist of the following at December 31, 2025 and 2024: Schedule of Intangible Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Estimated Useful Life (in years)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_z8jcaCCUAWra" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20241231_zHM0aUTKwLib" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNz2fq_zW9Q9ersUV6k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Capitalized software</td><td style="width: 2%"> </td> <td style="width: 16%; text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zW9N3c3zuZa" title="Finite-lived intangible assets, amortization method">3.0</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">223,390</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">223,390</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNz2fq_zFTDHuaa3V2c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(223,390</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(204,774</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNz2fq_zGm86SfnORo4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Capitalized software, net</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">18,616</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNetAbstract_iB_z5EDX28j4EG2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangible Assets:</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_i01I_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdJa6ZP9AR8c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">U.S. Method Patent</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zyav3Kv3ifIb" title="Finite-lived intangible assets, amortization method">13.4</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">967,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">967,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_i01I_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebDomainMember_zhnraiO1MSu1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Web Domain</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161,250</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsGross_i01I_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zmHHVqqXtDAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Trademark</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">N/A</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">483,750</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">483,750</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_i01I_maFLIANzGJu_zOznNXXiKYt5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Intangible assets</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,612,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,612,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzGJu_zAI7oWPAKxF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(324,503</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(252,391</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzGJu_zsUIEU8UXSA" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Intangible assets, net</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,287,997</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,360,109</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Capitalized software represents the development costs for the Company’s internal-use QHSLab platform software. The Company completed testing of its QHSLab platform software application at the end of the first quarter of 2022 and began to amortize the capitalized expenses on a straight-line basis over the useful life of the software. During the years ended December 31, 2025 and 2024 there was $18,616 and $74,463 of amortization expense, respectively. Amortization related to the QHSLab platform is recorded within cost of revenue on the Company’s consolidated statements of operations. There were no impairments recognized during the years ended December 31, 2025 and 2024. The intangible assets represent the value the Company paid to acquire the trademark “AllergiEnd”, the web domain “AllergiEnd.com” along with the U.S. Method Patent registration relating to the allergy testing kit and related materials the Company distributes to physician clients. The Company acquired the intangible assets from MedScience Research Group as of June 23, 2021 for total consideration of $<span id="xdx_909_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20210623__20210623__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MedScienceResearchGroupMember_zx8oilq2d82b" title="Acquired intangible assets">1,612,500 which was financed through a combination of restricted stock and a promissory note. The allocation of the purchase price to each of these assets was determined based on ASC 805-50-30, Business Combination, Related Issues, Initial Measurement. The assets are being amortized over their useful lives beginning July 1, 2021. The Trademark and Web Domain are determined to have an indefinite life and will be tested annually for impairment in accordance with ASC 350-30-35, Intangibles, General Intangibles Other Than Goodwill. There was $72,112 of amortization expense during each of the years ended December 31, 2025 and 2024. The Company evaluates intangible assets with infinite lives for impairment at least annually and evaluates intangible assets with finite lives when events or circumstances indicate an impairment may exist. No impairments or changes in useful lives were recognized during the years ended December 31, 2025 and 2024.

Non-current assets consist of the following at December 31, 2025 and 2024: Schedule of Intangible Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Estimated Useful Life (in years)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_z8jcaCCUAWra" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20241231_zHM0aUTKwLib" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNz2fq_zW9Q9ersUV6k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Capitalized software</td><td style="width: 2%"> </td> <td style="width: 16%; text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zW9N3c3zuZa" title="Finite-lived intangible assets, amortization method">3.0</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">223,390</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">223,390</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNz2fq_zFTDHuaa3V2c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(223,390</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(204,774</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNz2fq_zGm86SfnORo4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Capitalized software, net</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">18,616</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNetAbstract_iB_z5EDX28j4EG2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangible Assets:</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_i01I_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdJa6ZP9AR8c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">U.S. Method Patent</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zyav3Kv3ifIb" title="Finite-lived intangible assets, amortization method">13.4</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">967,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">967,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_i01I_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebDomainMember_zhnraiO1MSu1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Web Domain</td><td> </td> <td style="text-align: center">N/A</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161,250</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsGross_i01I_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zmHHVqqXtDAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Trademark</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">N/A</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">483,750</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">483,750</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_i01I_maFLIANzGJu_zOznNXXiKYt5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Intangible assets</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,612,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,612,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzGJu_zAI7oWPAKxF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(324,503</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(252,391</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzGJu_zsUIEU8UXSA" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Intangible assets, net</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,287,997</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,360,109</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

P3Y

223390

204774

18616

P13Y4M24D

967500

161250

483750

1612500

324503

252391

1287997

1360109

18616

74463

1612500

72112

Note 6. Loans Payable On June 23, 2021, the Company entered into a purchase agreement to acquire certain assets from MedScience Research Group, Inc (“MedScience”) (See Note 5 – Capitalized Software and Intangible Assets for additional information). As part of that purchase agreement, the Company issued a Promissory Note with a principal sum of $750,000. The principal, along with associated interest, were to be paid in 36 equal monthly installments that began in July 2021. The Promissory Note provides for various events of default similar to those provided for in similar transactions, including the failure to timely pay amounts due thereunder. In the event of a default, the interest rate on the outstanding principal would increase to a predetermined interest rate defined in the Promissory Note. The Company had deferred certain principal payments and MedScience indicated that it would forbear taking any action but reserved all of its rights under its agreement. The most recent notice of forbearance was received on March 20, 2025. The combined principal due along with accrued interest as of December 31, 2025 is $470,529 and as of December 31, 2024 was $433,334, without giving effect to additional interest of $49,165 and $30,567, respectively, which MedScience may have demanded as a result of the failure to make payments on the due dates provided in the Promissory Note. On December 31, 2025, the Company repurchased, cancelled, and extinguished the Promissory Note which had an outstanding principal and accrued interest balance totaling $470,529. In consideration for the repurchase of the Promissory Note, the Company issued an aggregate of 1,568,432 shares of its common stock. As of December 31, 2025, the principal loan balance and all accrued interest were discharged and had a $0 balance in the consolidated balance sheets. On November 12, 2025, the Company entered into a fixed-fee short-term loan with its merchant bank and received $114,400 in net loan proceeds. The loan is repaid by the merchant bank withholding an agreed-upon percentage of payments they process on behalf of the Company with a minimum of $14,262 paid every 60 days. The loan payable is due in May 2027. As of December 31, 2025, the loan balance was $90,704 and is split between current and non-current liabilities on the consolidated balance sheets. The December 31, 2024 loan balance of $66,294 is all recorded in current liabilities on the consolidated balance sheets.

750000

470529

433334

49165

30567

470529

1568432

114400

14262

90704

66294

Note 7. Convertible Notes Payable Convertible notes payable at December 31, 2025 and 2024 consist of the following: Schedule of Convertible Notes Payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231_zCdi3WJt4269" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20241231_zAF6KCWI54P6" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_ecustom--ConvertibleNotesPayableGross_iI_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember__us-gaap--DebtInstrumentAxis__custom--NoteOneShareholderMember_z56LCYflSb81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Note 1 – Shareholder</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">20,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">100,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ConvertibleNotesPayableGross_iI_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableTwoMember__us-gaap--DebtInstrumentAxis__custom--NoteTwoMercerNoteMember_z17evzc4hJu3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note 2 – Mercer Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">721,841</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--ConvertibleNotesPayableGross_iI_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember__us-gaap--DebtInstrumentAxis__custom--NoteThreeMercerNoteTwoMember_zADSwQgVEyhd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Note 3 – Mercer Note #2</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">462,306</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ConvertibleNotesPayableGross_iI_hus-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zrnEchx7UDfb" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible notes payable gross</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,284,147</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayableCurrent_iI_zgFZ5VV7LPK9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,284,147</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleLongTermNotesPayable_iI_zoNR4esKZME4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Note 1 – Effective May 7, 2021, the Company issued a Convertible Promissory Note in the original principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20210507__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember__us-gaap--DebtInstrumentAxis__custom--NoteOneShareholderMember_zUYfFJ6TQKhj" title="Face amount">100,000 to a shareholder (Note 1). The Note bears interest at a rate of ten percent (<span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210507__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember__us-gaap--DebtInstrumentAxis__custom--NoteOneShareholderMember_zw4UgKpqTYd6" title="Debt instrument interest rate stated percentage">10%) per annum. The terms and conditions of the Note may not be indicative of those that a third-party investor may agree to. The Note was originally scheduled to mature on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20210507__20210507__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember__us-gaap--DebtInstrumentAxis__custom--NoteOneShareholderMember_zTxhzoXvhhza" title="Debt instrument, maturity date">September 30, 2022. The maturity date was subsequently extended to December 31, 2023, further extended to December 31, 2024 during the quarter ended March 31, 2024, and further extended to December 31, 2025 during the quarter ended March 31, 2025. <span id="xdx_902_eus-gaap--DebtInstrumentDescription_c20210507__20210507__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember__us-gaap--DebtInstrumentAxis__custom--NoteOneShareholderMember_zGDVBEYnrXTf" title="Debt instrument, description">Pursuant to the terms of the Note, the outstanding principal and accrued interest were convertible, at the option of the holder, into shares of the Company’s common stock at a conversion price equal to the greater of (i) a twenty-five percent (25%) discount to the fifteen-day average market price of the Company’s common stock or (ii) $0.50 per share. On December 31, 2025, the Company entered into a Promissory Note Modification and Partial Conversion Agreement (“Modification Agreement”) with the holder of the Note. As of that date, the outstanding balance of the Note, including accrued interest, was $146,548. Pursuant to the Modification Agreement, the holder elected to convert $126,548 of outstanding principal and accrued interest into shares of the Company’s common stock at a conversion price of $0.30 per share. As a result of the conversion, the Company issued 421,827 shares of common stock. The converted portion of the Note was extinguished upon issuance of the shares. Following the partial conversion, a remaining balance of $20,000 continues to be outstanding under the Note. The maturity date of the remaining balance was extended to December 31, 2026. The remaining balance continues to bear interest at ten percent (10%) per annum and remains convertible at the option of the holder under the terms of the original Convertible Promissory Note. The Company may prepay the remaining balance, in whole or in part, at any time prior to maturity without penalty. As of December 31, 2025 and 2024, accrued interest on the Note totaled $<span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember__us-gaap--DebtInstrumentAxis__custom--NoteOneShareholderMember_zOFcgO7xh0e5" title="Interest payable, current">0 and $<span id="xdx_903_eus-gaap--InterestPayableCurrent_iI_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember__us-gaap--DebtInstrumentAxis__custom--NoteOneShareholderMember_zKGZXkdNXYAj" title="Interest payable, current">36,548, respectively. Accrued interest is included in other current liabilities on the accompanying consolidated balance sheets. Note 2 – Effective August 10, 2021, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which it issued to the investor an Original Issue Discount Secured Convertible Promissory Note (the “$806,000 Note”) in the principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20210810__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_zI72GDBaMXUc" title="Debt instrument, principal amount">806,000 and warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210810__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_z5ZMtTZcs2Y3" title="Warrants to purchase common stock">930,000 shares of the Company’s common stock for aggregate consideration of $<span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_c20210810__20210810__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_z9weXtUnvNw5" title="Proceeds from warrant exercises">750,000. In addition, pursuant to the Purchase Agreement the Company entered into a Registration Rights Agreement with the investor. The principal amount of the $806,000 Note and all interest accrued thereon was payable on August 10, 2022, and was secured by a lien on substantially all of the Company’s assets. The $806,000 Note provided for interest at the rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220810__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember_z6xfRnAB2RF" title="Debt instrument interest rate stated percentage">5% per annum, payable at maturity, and was convertible into common stock at a price of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220810__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zES1anF6wjZ5" title="Debt instrument convertible conversion price per share">0.65 per share. In addition to customary anti-dilution adjustments upon the occurrence of certain corporate events, the $806,000 Note provided, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the $806,000 Note, at a per share price lower than the conversion price then in effect, the conversion price would be reduced to the per share price at which such stock or common stock equivalents were sold. The $806,000 Note provided for various events of default similar to those provided for in similar transactions, including the failure to timely pay amounts due thereunder. In the event of a default, the interest rate on the outstanding principal would increase during the continuance of the default to a Default Interest Rate defined in the $806,000 Note. Additionally, all outstanding amounts would be paid at the holder’s discretion at a Mandatory Default Amount also defined in the $806,000 Note. On November 11, 2021, Mercer Street Global Opportunity Fund, LLC (“Mercer Fund”), converted $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20211111__20211111__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zW1KUYYAEKyk" title="Conversion of notes payable">50,000 of the principal amount of the $806,000 Note into <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20211111__20211111__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zrjGHIJW8RX8" title="Conversion of notes payable, shares">76,923 shares of the Company’s common stock at a price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211111__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zfCUu6Fafie9" title="Debt instrument convertible conversion price per share">0.65 per share. The <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211111__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zrSqtnBLycJ4" title="Number of securities called by warrants or rights">930,000 Warrants were initially exercisable for a period of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20211111__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgXAxYL3SZkd" title="Warrants term">three years at a price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211111__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqhmsvOlqPOg" title="Exercise price of warrants or rights">1.25 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant. The shares issuable upon conversion of the $806,000 Note and exercise of the Warrants were to be registered under the Securities Act of 1933, as amended, for resale by the investor as provided in the Registration Rights Agreement. The Warrants may be exercised by means of a “cashless exercise” if at any time the shares issuable upon exercise of the Warrant are not covered by an effective registration statement. As a result of the issuance of a $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20220719__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zsxw0NCeRpo8" title="Debt instrument, principal amount">440,000 Original Issue Discount Secured Convertible Promissory Note effective July 19, 2022 (the “$440,000 Note”), (Note 3) convertible into shares of the Company’s common stock at a price of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220719__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ziEhcvQH84nl" title="Debt instrument convertible conversion price per share">0.20 per share, the price at which the $806,000 Note may be converted into shares of the Company’s common stock had been reduced to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220719__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhxeeoIWBH52" title="Debt instrument convertible conversion price per share">0.20 per share. On July 27, 2022, Mercer Fund converted $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pid_c20220727__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember_zG4kO8YrDBr" title="Debt instrument face amount">50,000 of the principal amount of the $806,000 Note into <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220726__20220727__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember_zDVRSrHV0gf3" title="Conversion of notes payable, shares">250,000 shares of the Company’s common stock at a price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220727__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember_zuYDro0aRdlc" title="Debt instrument convertible conversion price per share">0.20 per share. On October 5, 2023, at the request of Mercer Fund, the Company agreed to reduce the conversion price with respect to $<span id="xdx_901_eus-gaap--DebtInstrumentDecreaseForgiveness_c20231005__20231005__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_zoau1kSJfNKj" title="Increase decrease in conversion price">10,500 of the amounts payable pursuant to the $806,000 Note to two and one-half ($<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20231005__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_ze7UjeQlv8Cg" title="Conversion per share price">0.025) cents per share. The balance of the amounts payable pursuant to the $806,000 Note remain convertible into shares of common stock of the Company at a price of twenty ($<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_uUSDPShares_c20231005__20231005__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_zsI4dMd55sIk" title="Conversion per share price">0.20) cents per share. On March 4, 2024, at the request of Mercer Fund, the Company agreed to reduce the conversion price with respect to $<span id="xdx_90A_eus-gaap--DebtInstrumentDecreaseForgiveness_c20240304__20240304__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_zZW2mCoCPtm9" title="Increase decrease in conversion price">12,000 of the amounts payable pursuant to the $806,000 Note to two and one-half ($<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20240304__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_zmo0DRFxf8oc" title="Conversion per share price">0.025) cents per share. The balance of the amounts payable pursuant to the $806,000 Note remain convertible into shares of common stock of the Company at a price of twenty ($<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_uUSDPShares_c20240304__20240304__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_zdUnQX2lLto8" title="Conversion per share price">0.20) cents per share. On February 19, 2024, the Company received the most recent notice from the manager of Mercer Fund of its agreement to forebear from the exercise of any rights it might have as a result of any defaults under the $806,000 Note and the related documents between the Company and the Mercer Fund, provided that the Mercer Fund reserved all of its rights under such agreements. The $806,000 Note continued to accrue interest at 5%. On January 6, 2025, Mercer Fund converted $25,000 of the principal amount of the $806,000 Note into <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250106__20250106__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_zLyC1ATwIHRh" title="Conversion of notes payable, shares">125,000 shares of the Company’s common stock at a price of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20250106__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_zZe62AnvPK5f" title="Debt instrument convertible conversion price per share">0.20 per share. On January 13, 2025, Mercer Fund converted $50,000 of the principal amount of the $806,000 Note into <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250113__20250113__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_zPcwQItyy71h" title="Conversion of notes payable, shares">250,000 shares of the Company’s common stock at a price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20250113__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_zXZAS1IQjQOb" title="Debt instrument convertible conversion price per share">0.20 per share. On February 20, 2025, the Company received a Notice of Default from Mercer Fund in connection with the $806,000 Note. Under the terms of the $806,000 Note, a failure to pay the principal and interest when due constitutes an Event of Default under Section 7(a)(i) of the Note. The Note matured on August 10, 2022 and remained unpaid. Therefore, as of December 31, 2024, the Company combined the accrued interest as of the default date into the outstanding principal balance of the $806,000 Note and had accrued cumulative default interest of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--EightLakhSixThousandNoteMember_zRyw3zvnLp27" title="Accrued interest">18% on that balance. On May 12, 2025, the Mercer Fund assigned all of its interest in and to, and duties and obligations under the $806,000 Note to Catheter Precision, Inc. (“Catheter”) in connection with the acquisition by Mercer Fund of certain securities of Catheter. On November 18, 2025, the Company consummated a Note Repurchase Agreement (the “Repurchase Agreement”) with Catheter, the holder of the Company’s $806,000 Note and $440,000 Note (collectively, the “Notes”). The Notes, which had been in default and bore interest at a default rate of 18 percent per annum, had an aggregate outstanding balance consisting of principal and accrued interest of $1,445,695 as of the date of redemption. See additional details under Note 3 below. As of December 31, 2025, the balance of the $806,000 Note and all accrued interest was $0 on the consolidated balance sheets. As of December 31, 2024, all original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, have been recognized. The remaining principal balance of $721,841, which includes the accrued interest as of the default date, along with the default interest, is recorded within current liabilities on the Company’s consolidated balance sheets. After giving effect to payments totaling $163,044 made during the year ended December 31, 2024, the $806,000 Note had $158,038 of accrued interest as of December 31, 2024 recorded in current liabilities on the consolidated balance sheets. Note 3 – Effective July 19, 2022, the Company entered into a Securities Purchase Agreement with Mercer Fund pursuant to which it issued the $440,000 Note in the principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20220719__us-gaap--DebtInstrumentAxis__custom--FourLakhFourtyThousandNoteMember__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcw4xlWWeiC3" title="Debt instrument, principal amount">440,000 and warrants to purchase <span id="xdx_90A_ecustom--WarrantsIssuedToPurchaseOfCommonStock_iI_c20220719__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--FourLakhFourtyThousandNoteMember_zVIF21UfXfk5" title="Warrants to purchase common stock">550,000 shares of the Company’s common stock for aggregate consideration of $<span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_c20220719__20220719__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--FourLakhFourtyThousandNoteMember_zNcpjjljaXDg" title="Proceeds from warrant exercises">400,000. In addition, pursuant to the Purchase Agreement the Company entered into a Registration Rights Agreement with Mercer Fund. The principal amount of the $440,000 Note and all interest accrued thereon was payable on July 19, 2023, and were secured by a lien on substantially all of the Company’s assets. The $440,000 Note provides for interest at the rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230719__us-gaap--DebtInstrumentAxis__custom--FourLakhFourtyThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember_zaqXovnORHRj" title="Debt instrument interest rate stated percentage">5% per annum, payable at maturity, and was convertible into common stock at a price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230719__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--DebtInstrumentAxis__custom--FourLakhFourtyThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zirhcR3PYEKc" title="Debt instrument convertible conversion price per share">0.20 per share. In addition to customary anti-dilution adjustments upon the occurrence of certain corporate events, the $440,000 Note provided, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the $440,000 Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such stock or common stock equivalents were sold. The $440,000 Note provided for various events of default similar to those provided for in similar transactions, including the failure to timely pay amounts due thereunder. The $440,000 Note provided further that the Company will be liable to the Mercer Fund for various amounts, including the cost of a buy-in, if the Company shall default in its obligation to register the shares issuable upon conversion of the $440,000 Note for sale by the Mercer Fund under the Securities Act or otherwise fails to facilitate Buyer’s sale of the shares issuable upon conversion of the $440,000 Note as required by the terms of the $440,000 Note. In the event of a default, the interest rate on the outstanding principal would increase during the continuance of the default to a Default Interest Rate defined in the $440,000 Note. Additionally, all outstanding amounts would be paid at the holder’s discretion at a Mandatory Default Amount also defined in the $440,000 Note. On February 19, 2024, the Company received the most recent notice from the manager of the Mercer Fund, LLC that it agreed to forebear from exercising any rights it might have as a result of any defaults under the $440,000 Note and the related documents between the Company and the Fund, provided that it reserved all of its rights. On February 20, 2025, the Company received a Notice of Default from Mercer Fund in connection with the $440,000 Note. Under the terms of the $440,000 Note, a failure to pay the principal and interest when due constitutes an Event of Default under Section 7(a)(i) of the Note. The Note matured on July 22, 2023 and remains unpaid. Therefore, as of December 31, 2024, the Company combined the accrued interest as of the default date into the outstanding principal balance of the $440,000 Note and has accrued cumulative default interest of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--FourLakhFourtyThousandNoteMember_zgETspE6LWka" title="Accrued interest">18% on that balance. The <span id="xdx_907_ecustom--WarrantsIssuedToPurchaseOfCommonStock_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--FourLakhFourtyThousandNoteMember_zcCuFKlJtuf3" title="Warrants issued to purchase of common stock">550,000 Warrants were initially exercisable for a period of <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember__us-gaap--DebtInstrumentAxis__custom--FourLakhFourtyThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zwyqJbdZlIM1" title="Warrants term">three years at a price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember__us-gaap--DebtInstrumentAxis__custom--FourLakhFourtyThousandNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--MercerStreetGlobalOpportunityFundLLCMember_zU6Ek0TIT8Y7" title="Exercise price of warrants or rights">0.50 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant. The shares issuable upon conversion of the $440,000 Note and exercise of the Warrants were to be registered under the Securities Act of 1933, as amended, for resale by the investor as provided in the Registration Rights Agreement. The Warrants may be exercised by means of a “cashless exercise” if at any time the shares issuable upon exercise of the Warrant are not covered by an effective registration statement. The Company accounts for the allocation of its issuance costs related to its Warrants in accordance with ASC 470-20, Debt with Conversion and Other Options. Under this guidance, if debt or stock is issued with detachable warrants, the proceeds need to be allocated to the two instruments using either the fair value method, the relative fair value method, or the residual value method. The Company used the relative fair value at the time of issuance to allocate the value received between the convertible note and the warrants. The Company estimated the fair value of the Warrants utilizing the Black-Scholes pricing model, which is dependent upon several assumptions such as the expected term of the Warrants, expected volatility of the Company’s stock price over the expected term, expected risk-free interest rate over the expected term and expected dividend yield rate over the expected term. The Company believes this valuation methodology is appropriate for estimating the fair value of warrants. The value allocated to the relative fair value of the Warrants was recorded as debt issuance costs and additional paid in capital. The principal, net of the original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, which were being recognized over the life of the $440,000 Note, along with associated interest, was recorded with current liabilities on the Company’s consolidated balance sheets. On May 12, 2025, the Mercer Fund assigned all of its interest in and to, and duties and obligations under the $440,000 Note to Catheter in connection with the acquisition by Mercer Fund of certain securities of Catheter. On November 18, 2025, the Company consummated the Repurchase Agreement with the holder of the Notes. The Notes, which had been in default and bore interest at a default rate of 18 percent per annum, had an aggregate outstanding balance consisting of principal and accrued interest of $1,445,695 as of the date of redemption. Under the terms of the Repurchase Agreement, the Company purchased the Notes for a cash payment of $300,000. Upon payment of the Repurchase Price, the Notes were deemed fully satisfied, cancelled, and extinguished, and all security interests, liens, guarantees, claims, rights, and obligations relating to the Notes were released and terminated. The redemption resulted in the termination of all conversion rights associated with the Notes, including rights to convert into shares of the Company’s common stock at a conversion price of $0.20 per share and a Gain on extinguishment of $1,145,695 in the consolidated income statement for the year ended December 31, 2025. As of December 31, 2025, the balance of the $440,000 Note and all accrued interest was $0 on the consolidated balance sheets. As of December 31, 2024, all original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, have been recognized. The remaining principal balance of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember__us-gaap--DebtInstrumentAxis__custom--FourLakhFourtyThousandNoteMember_zKD5P1UCkeHi">462,306, which includes the accrued interest as of the default date, along with the default interest, is recorded within current liabilities on the Company’s consolidated balance sheets. After giving effect to payments totaling $<span id="xdx_90A_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--FourLakhFourtyThousandNoteMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember_zNWj8Eytr5c8" title="Payments of debt issuance costs">51,956 made during the year ended December 31, 2024, the $440,000 Note had $<span id="xdx_90B_eus-gaap--InterestPayableCurrent_iI_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember__us-gaap--DebtInstrumentAxis__custom--FourLakhFourtyThousandNoteMember_z1sjtgzw1c04">70,092 of accrued interest, as of December 31, 2024 recorded in current liabilities on the consolidated balance sheets.

Convertible notes payable at December 31, 2025 and 2024 consist of the following: Schedule of Convertible Notes Payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231_zCdi3WJt4269" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20241231_zAF6KCWI54P6" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_ecustom--ConvertibleNotesPayableGross_iI_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember__us-gaap--DebtInstrumentAxis__custom--NoteOneShareholderMember_z56LCYflSb81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Note 1 – Shareholder</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">20,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">100,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ConvertibleNotesPayableGross_iI_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableTwoMember__us-gaap--DebtInstrumentAxis__custom--NoteTwoMercerNoteMember_z17evzc4hJu3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note 2 – Mercer Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">721,841</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--ConvertibleNotesPayableGross_iI_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember__us-gaap--DebtInstrumentAxis__custom--NoteThreeMercerNoteTwoMember_zADSwQgVEyhd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Note 3 – Mercer Note #2</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">462,306</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ConvertibleNotesPayableGross_iI_hus-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zrnEchx7UDfb" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible notes payable gross</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,284,147</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayableCurrent_iI_zgFZ5VV7LPK9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,284,147</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleLongTermNotesPayable_iI_zoNR4esKZME4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

20000 100000 721841 462306 20000 1284147

20000

1284147

100000

0.10

2022-09-30

Pursuant to the terms of the Note, the outstanding principal and accrued interest were convertible, at the option of the holder, into shares of the Company’s common stock at a conversion price equal to the greater of (i) a twenty-five percent (25%) discount to the fifteen-day average market price of the Company’s common stock or (ii) $0.50 per share

146548

126548

0.30

421827

20000

36548

806000

930000

750000

0.05

0.65

50000

76923

0.65

930000

P3Y

1.25

440000

0.20

50000

250000

0.20

10500

0.025

0.20

12000

0.025

0.20

25000

125000

0.20

50000

250000

0.20

2022-08-10

0.18

440000

1445695

721841

163044

158038

440000

550000

400000

0.05

0.20

2023-07-22

0.18

550000

P3Y

0.50

1445695

0.20

1145695

462306

51956

70092

Note 8. Preferred Stock and Private Placement Offering of Common Stock Issuance of Common Stock and Warrants in a Private Placement Offering On December 26, 2025, the Company accepted subscription agreements from two accredited investors for the purchase of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20251226__20251226__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGOjhMdSNZ6k" title="Common stock and warrants in a private placement offering">499,998 of the Company common stock and warrants in a private placement offering. Pursuant to the subscription agreements, the Company issued an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251226__20251226__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIe7WhJjcYui" title="Common stock and warrants in a private placement offering">1,666,663 shares of common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251226__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zxMSbYcSvlNe" title="Common stock, par value">0.0001 per share, at a purchase price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20251226__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zuF9WqiuiAza" title="Purchase price, per share">0.30 per share, together with an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251226__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHXweciq21wi" title="Warrants to purchase shares of common stock">416,666 warrants to purchase shares of common stock. Each warrant is exercisable at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251226__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zo5V589f08sl" title="Warrants exercise price, per share">0.60 per share and expires on <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251226__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_znfOixecx6k2" title="Warrants expires date">December 31, 2030. Issuance of Series A Preferred Stock The shares of Series A Preferred Stock have a stated value of $0.25 per share and are initially convertible into shares of common stock at a price of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210621__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjDPlVA07gda" title="Debt instrument convertible conversion price per share">0.05 per share (subject to adjustment upon the occurrence of certain events). The Series A Preferred Stock does not accrue dividends and ranks prior to the common stock upon a liquidation of the Company. The Series A Preferred Stock votes on all matters brought before the shareholders together with the Common stock as a single class and each share of Series A Preferred Stock has a number of votes, initially 5, equal to the number of shares of preferred stock into which it is convertible as of the record date for any vote. Issuance of Series A-2 Preferred Stock The shares of Series A-2 Preferred Stock have a stated value of $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPriceIncrease_c20211229__20211230__us-gaap--StatementClassOfStockAxis__custom--SeriesA2PreferredStockMember_zvCPvfPXxSth" title="Preferred stock stated value">0.16 per share and are convertible into shares of common stock at a price of $<span id="xdx_906_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20211229__20211230__us-gaap--StatementClassOfStockAxis__custom--SeriesA2PreferredStockMember_zqgSSQrfEcB3" title="Number of shares convertible into common stock price per share">0.16 per share (subject to adjustment upon the occurrence of certain events). The rights of holders of the Company’s common stock with respect to the payment of dividends and upon liquidation are junior in right of payment to holders of the Series A-2 Convertible Preferred Shares. The rights of the holders of the Company’s Series A-2 Preferred Shares are pari passu to the rights of the holders of the Company’s Series A Preferred Shares currently outstanding. Holders of the Series A-2 Convertible Preferred Stock will vote on an as converted basis with the holders of the Company’s common stock and Series A Preferred Stock as to all matters to be voted on by the holders of the common stock. Each Series A-2 Preferred Share shall be entitled to a number of votes equal to five times the number of shares of common stock into which it is then convertible on the applicable record date. Holders of the Series A-2 Convertible Preferred Stock are entitled to receive cumulative dividends at an annual rate of <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2PreferredStockMember_z5YdiSmSip4" title="Preferred stock, cumulative dividend annual rate, percentage">7% and payable annually in cash or shares of common stock at the election of the Company in accordance with the Series A-2 Convertible Stock agreement. As of December 31, 2025, the holders of the series A-2 Preferred Stock had received <span id="xdx_902_eus-gaap--CommonStockDividendsShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA2PreferredStockMember_zk8CfzhRdCXi" title="Common stock dividends shares">94,339 shares of common stock in satisfaction of dividends accrued through December 31, 2025. During the year ended December 31, 2024, the holders of series A-2 Preferred Stock had received <span id="xdx_909_eus-gaap--CommonStockDividendsShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA2PreferredStockMember_zSIKwWae5NFe" title="Common stock dividends shares">491,019 shares of common stock in satisfaction of dividends accrued through December 31, 2024.

499998

1666663

0.0001

0.30

416666

0.60

2030-12-31

0.25

0.05

0.16

0.07

94339

491019

Note 9. Income and (Loss) Per Common Share The Company calculates net income or loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net income (loss) per common share were determined by dividing net income (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, include shares issuable upon exercise or conversion of outstanding common stock options, common stock warrants, convertible debt and preferred shares which may be used to purchase common stock or receive common stock upon the conversion of issued and outstanding preferred stock, if those options, warrants, debt and preferred shares are exercisable or convertible and at prices below the average share price for the period. For the year ended December 31, 2025, 8,044,884 of common equivalent shares related to Preferred Shares A and A-2 were added to the basic weighted average shares outstanding to arrive at the diluted weighted average shares outstanding while other potentially dilutive shares were excluded from the calculation based on the exercises price of those shares. For the period ended December 31, 2024, the Company’s potentially dilutive shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive since the Company incurred a loss in such period. <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z3xULdbqUcpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Schedule of Anti-dilutive Securities Excluded from Calculation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20251231_zgUYFb6Yikr8" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240101__20241231_zwQv9YkUlEi5" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Common equivalent shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,044,884</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzDb3T92Qdz2" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: justify">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,100,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpHqYUj4Z4Fg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Stock warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">416,666</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">550,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zkejPcpHZN9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total shares excluded from calculation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">416,666</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,694,884</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zbzgY3VZVsG3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Antidilutive securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">416,666</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,694,884</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

8044884

<p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z3xULdbqUcpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Schedule of Anti-dilutive Securities Excluded from Calculation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20251231_zgUYFb6Yikr8" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240101__20241231_zwQv9YkUlEi5" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Common equivalent shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,044,884</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzDb3T92Qdz2" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: justify">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,100,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpHqYUj4Z4Fg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Stock warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">416,666</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">550,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zkejPcpHZN9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total shares excluded from calculation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">416,666</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,694,884</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zbzgY3VZVsG3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Antidilutive securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">416,666</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,694,884</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

1100000

416666

550000

416666

9694884

416666

9694884

Note 10. Stock-based Compensation During the years ended December 31, 2025 and 2024, there was no stock-based compensation associated with stock options included in research and development expense. The Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQH9tEyR6T98" title="Common stock for services"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zENw0wwnkchi" title="Common stock for services">100,000 shares of common stock for services during each of the years ended December 31, 2025 and 2024. A portion of these shares related to services that had not yet been performed at the time of issuance and were recorded as prepaid expenses. Such prepaid amounts were subsequently recognized as expense as the related services were performed. Accordingly, the Company recognized $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20251231__custom--IncomeStatementsLocationAxis__custom--ResearchAndDevelopmentExpensesMember_zykjr7xQDfci" title="Share issued for services in research and development">7,550 and $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20241231__custom--IncomeStatementsLocationAxis__custom--ResearchAndDevelopmentExpensesMember_zEz1glnaDmBd" title="Share issued for services in research and development">1,258, respectively, of expense associated with shares issued for services in research and development, and $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20251231__custom--IncomeStatementsLocationAxis__custom--GeneralAndAdministrativeExpensesMember_z7god9l58POd" title="Share issued for services in research and development">19,250 and $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20241231__custom--IncomeStatementsLocationAxis__custom--GeneralAndAdministrativeExpensesMember_zDwHlabIqY6a" title="Share issued for services in research and development">0, respectively, in general and administrative expense. There were no options granted during the years ended December 31, 2025 and 2024. There were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_do_c20250101__20251231_znQuYAQb2w4h" title="Options exercised, forfeited or cancelled">no options exercised, forfeited or cancelled during either period but all options did expire during the year ended December 31, 2025. As of December 31, 2024, all compensation related to the 1,100,000 outstanding options has been recognized. The options were expensed over the vesting period for each Advisor. <p id="xdx_897_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_z9Vqciykdyhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">All outstanding options expired during the year ended December 31, 2025. Options outstanding at December 31, 2024 consist of: Schedule of Options Outstanding and Exercisable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Date Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Exercisable</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionIssuanceDate_dd_c20250101__20251231__us-gaap--AwardTypeAxis__custom--OptionOneMember_znv8Qwf9lZEb" title="Date Issued">June 27, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--OptionOneMember_ztCit2tUwuF5" style="width: 14%; text-align: right" title="Number Outstanding">150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--OptionOneMember_z4ZAX1zSWzw6" style="width: 14%; text-align: right" title="Number Exercisable">150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--OptionOneMember_zPLNtDgaZvqc" style="width: 14%; text-align: right" title="Exercise Price">0.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250101__20251231__us-gaap--AwardTypeAxis__custom--OptionOneMember_z0AkXYLPuOR1" title="Expiration Date">June 27, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionIssuanceDate_dd_c20250101__20251231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zPLRsWZAtja7" title="Date Issued">January 1, 2021</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zKab1ktUlCDd" style="border-bottom: Black 1pt solid; text-align: right" title="Number Outstanding">450,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_ziFhyIGd3Obd" style="border-bottom: Black 1pt solid; text-align: right" title="Number Exercisable">450,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zqOrzAJKVBo2" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">0.65</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250101__20251231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zWVYmClNUQGf" title="Expiration Date">December 31, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zfkbHK9xUD32" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number Outstanding">600,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zRXmjfGJFus5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number Exercisable">600,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td></tr> </table> Warrants outstanding at December 31, 2025 consist of: Schedule of Warrants Outstanding and Exercisable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Date Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Exercisable</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; padding-bottom: 1pt"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuanceDate_dd_c20250101__20251231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zwwrZhYz4zC9" title="Date Issued">December 31, 2025</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zqPjI4CH22u5" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Number Outstanding">416,666</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zlQuo3yjb2vl" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Number Exercisable">416,666</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zQgECakOpYd3" style="padding-bottom: 1pt; width: 14%; text-align: right" title="Exercise Price">0.60</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 16%; text-align: right; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250101__20251231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zEKXi6GEcICc" title="Expiration Date">December 31, 2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlaWNxTl1yRh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number Outstanding">416,666</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqDo4ru7z5Jf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number Exercisable">416,666</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td></tr> </table> Warrants outstanding at December 31, 2024 consist of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Date Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Exercisable</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; padding-bottom: 1pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuanceDate_dd_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zhHep4H91zYc" title="Date Issued">July 19, 2022</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zkp5o6Xeeto9" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Number Outstanding">550,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zE5fPy3Alm79" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Number Exercisable">550,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zlUy5wwwKHg2" style="padding-bottom: 1pt; width: 14%; text-align: right" title="Exercise Price">0.50</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 16%; text-align: right; padding-bottom: 1pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zamxKXE2sd54" title="Expiration Date">July 18, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z86jxU4D6KXf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number Outstanding">550,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdICq672s9za" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number Exercisable">550,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td></tr> </table>

100000

7550

1258

19250

1100000

<p id="xdx_897_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_z9Vqciykdyhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">All outstanding options expired during the year ended December 31, 2025. Options outstanding at December 31, 2024 consist of: Schedule of Options Outstanding and Exercisable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Date Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Exercisable</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionIssuanceDate_dd_c20250101__20251231__us-gaap--AwardTypeAxis__custom--OptionOneMember_znv8Qwf9lZEb" title="Date Issued">June 27, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--OptionOneMember_ztCit2tUwuF5" style="width: 14%; text-align: right" title="Number Outstanding">150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--OptionOneMember_z4ZAX1zSWzw6" style="width: 14%; text-align: right" title="Number Exercisable">150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--OptionOneMember_zPLNtDgaZvqc" style="width: 14%; text-align: right" title="Exercise Price">0.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250101__20251231__us-gaap--AwardTypeAxis__custom--OptionOneMember_z0AkXYLPuOR1" title="Expiration Date">June 27, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionIssuanceDate_dd_c20250101__20251231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zPLRsWZAtja7" title="Date Issued">January 1, 2021</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zKab1ktUlCDd" style="border-bottom: Black 1pt solid; text-align: right" title="Number Outstanding">450,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_ziFhyIGd3Obd" style="border-bottom: Black 1pt solid; text-align: right" title="Number Exercisable">450,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zqOrzAJKVBo2" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">0.65</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250101__20251231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zWVYmClNUQGf" title="Expiration Date">December 31, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zfkbHK9xUD32" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number Outstanding">600,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zRXmjfGJFus5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number Exercisable">600,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td></tr> </table>

2020-06-27

150000

0.40

2025-06-27

2021-01-01

450000

0.65

2025-12-31

600000

Warrants outstanding at December 31, 2025 consist of: Schedule of Warrants Outstanding and Exercisable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Date Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Exercisable</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; padding-bottom: 1pt"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuanceDate_dd_c20250101__20251231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zwwrZhYz4zC9" title="Date Issued">December 31, 2025</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zqPjI4CH22u5" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Number Outstanding">416,666</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zlQuo3yjb2vl" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Number Exercisable">416,666</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zQgECakOpYd3" style="padding-bottom: 1pt; width: 14%; text-align: right" title="Exercise Price">0.60</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 16%; text-align: right; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250101__20251231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zEKXi6GEcICc" title="Expiration Date">December 31, 2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlaWNxTl1yRh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number Outstanding">416,666</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_iI_pid_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqDo4ru7z5Jf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number Exercisable">416,666</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td></tr> </table>

2025-12-31

416666

416666 0.60

2030-12-31

416666

416666 2022-07-19

550000

550000 0.50

2025-07-18

550000

Note 11. Related-Party Transactions Due to Related Parties: Amounts due to related parties consist of cash advances received from the Company’s principal shareholder. Some advances bear no interest and are due on demand while a portion has been converted into a loan to the principal shareholder that provides interest at a rate of 10% per annum. These terms and conditions may not be indicative of what a third-party investor may agree to. As of December 31, 2025 and 2024 amounts due to related-parties totaled $91,085 and $13,536, respectively. As of December 31, 2025, $91,085 is included in non-current liabilities as a $90,000 loan and accrued interest that matures on March 31, 2027. As of December 31, 2024, there is $13,536 included in other current liabilities on the Company’s consolidated balance sheets in connection with advances from the principal shareholder. The Company’s CEO and principal shareholder is a shareholder of MedScience. In addition, the CEO provides services to MedScience for which he is compensated. Convertible notes payable, related party: See Note 7.

0.10

91085

13536

91085

90000

13536

Note 12. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. Given its history of net operating losses, the Company has determined that it is more likely than not that it will not be able to realize the tax benefit of its net operating loss carryforwards. Accordingly, the Company has not recognized a deferred tax asset for this benefit. The valuation allowance at December 31, 2025 and 2024 was $794,639 and $890,924, respectively. The net change in valuation allowance for the year ended December 31, 2025 was a decrease of $96,285 and for the year ended December 31, 2024 was an increase of $54,440. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. That realization is dependent upon the future generation of taxable income during the period in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred income tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on these considerations, the Company has determined that enough uncertainty exists regarding the realization of the deferred tax asset balance to apply a full valuation allowance against these assets as of December 31, 2025 and 2024. All tax years remain open for examination by taxing authorities. Reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% for 2025 and 2024 are as follows: Schedule of Effective Income Tax Reconciliation <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250101__20251231_z7i5KixKiv9k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zm1CJb6xv7Y1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maCc_zv5raTbLofch" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Income tax at federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maCc_zX4CIZ1zlMz2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(21.00</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(21.00</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtCc_zZkx2Wbx4C0f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company has net operating losses of $3,903,551 which begin to expire in 2027. Future utilization of currently generated federal and state NOL and tax credit carry forwards may be subject to a substantial annual limitation due to the ownership change limitations. The annual limitation may result in the expiration of NOL and tax credit carry-forwards before full utilization.

794639

890924

96285

54440

Reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% for 2025 and 2024 are as follows: Schedule of Effective Income Tax Reconciliation <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250101__20251231_z7i5KixKiv9k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zm1CJb6xv7Y1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maCc_zv5raTbLofch" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Income tax at federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maCc_zX4CIZ1zlMz2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(21.00</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(21.00</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtCc_zZkx2Wbx4C0f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.2100

-0.2100

3903551

begin to expire in 2027

Note 13. Segment Information The Company’s Chief Executive Officer (“CEO”) is the CODM and allocates resources and assesses performance based upon consolidated Net loss that is included in the accompanying consolidated statements of operations. Accordingly, the Company operates as a single operating segment. The measure of segment assets is reflected as Total assets in the accompanying consolidated balance sheets. The Company’s revenue is derived from providing Primary Care Physicians (“PCP’s”) with relevant value-based tools to enable them to diagnose and treat their patients. See additional discussion of revenue in Note 3 - Basis of Presentation.

Note 14. Commitments and Contingencies There are no actual, pending or threatened legal proceedings as of December 31, 2025. The Company has no non-cancellable operating leases.

Note 15. Subsequent Events Management has evaluated subsequent events through the date of this filing.